Dear EURETINA Members, A very warm welcome to the August 8th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 8th, 2024 “EURETINA-Brief”© Issue No. 297
In a recent study published in the prestigious journal Nature Communications (2024 Jul 21;15[1]:6150), researchers have reported that an upstream regulator, “AKT2” (a member of… Read More »Researchers identify that lysosomal biogenesis and mitochondrial signalling may suggest new therapeutic targets for dry-AMD.
Researchers at Janssen Pharmaceuticals N.V. and the ERN-EYE Network at the Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, Padua, Italy, have reported results… Read More »Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) have announced the receipt of Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of IRDs, including… Read More »Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.
Dear EURETINA Members, A very warm welcome to the July 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 24th, 2024 “EURETINA-Brief”© Issue No. 296
Researchers at the School of Pharmacy, University of Eastern Finland, and the Gavin Herbert Eye Institute-Center for Translational Vision Research, Department of Ophthalmology, University of… Read More »Re-purposed drugs for retinitis pigmentosa may address mutation-independent approach for retinal degenerations.
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, have reported a detailed natural history, retinal imaging dataset and clinical features… Read More »A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.
A private biotech company, Beacon Therapeutics, based in London, UK (and Florida and Cambridge, USA), has received an investment of $170M from several funding partners,… Read More »Beacon Therapeutics has announced an investment of $170M for the development of ophthalmic gene therapies.
According to the Royal College of Ophthalmologists, the term of “low vision” is not defined in UK legislation however, the UK Low Vision Services Consensus… Read More »Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration.
